Trinity Biotech plc (NASDAQ: TRIB) is a global medical diagnostics company focused on developing, manufacturing and marketing products for the management of chronic diseases. The company’s core product lines address diabetes, celiac disease and other autoimmune disorders through a combination of point-of-care analyzers, rapid immunoassays and laboratory-based systems. Trinity Biotech aims to support healthcare professionals with reliable diagnostic tools that facilitate early detection, monitoring and treatment decisions.
In the diabetes market, Trinity Biotech offers a range of hemoglobin A1c (HbA1c) test systems designed for physician offices, clinics and central laboratories. These analyzers provide quantitative results that help assess long-term glucose control. For celiac disease, the company’s portfolio includes enzyme-linked immunosorbent assays (ELISA) and rapid cassette tests that detect disease-specific antibodies. Additionally, Trinity Biotech produces specialty assays for thyroid function, vitamin D and other endocrinological markers, as well as quality controls and calibrators that support laboratory accreditation requirements.
Founded in 1982 and headquartered in Carlsbad, California, with operational facilities in Ireland and strategic offices worldwide, Trinity Biotech serves customers across North America, Europe, Latin America and the Asia-Pacific region. The company’s manufacturing operations adhere to international regulatory standards, including ISO certification and U.S. Food and Drug Administration (FDA) approvals. Trinity Biotech maintains strategic collaborations with research institutions and distribution partners to broaden its market reach and accelerate the launch of new diagnostic solutions.
Under the leadership of Chief Executive Officer Daniel Rowe and an experienced management team, Trinity Biotech continues to invest in research and development to expand its immunoassay platform and enhance product automation. The company places a strong emphasis on clinical validation, regulatory compliance and customer support, positioning itself to address the growing global demand for chronic disease testing and contribute to improved patient outcomes.
AI Generated. May Contain Errors.